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Abstract
Short interfering double-stranded RNAs (siRNAs) expressed under the control of an RNA polymerase I promoter system were used to
target gene expression of influenza A and West Nile virus. Decreased RNA and protein expression was induced in a sequence-specific
manner—reducing sequence complementarity from 21 to 17 nucleotides abrogated the siRNA effect. Reduced M2 expression resulted in a
decrease in total and infectious influenza A virus production. WNV protein expression, genomic RNA, and infectious virus production were
all dramatically reduced by siRNAs targeting two distinct viral sequences. The data demonstrate the utility of plasmid-driven siRNAs in
regulating the expression of single viral genes, global viral gene expression, as a potential antiviral treatment, and as a genetic tool for viruses
whose genomes are difficult to manipulate.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The use of short interfering RNAs (siRNAs) in down
regulating or “knocking down” gene expression has been
demonstrated recently in a variety of mammalian systems
(Elbashir et al., 2001a,b,c; Garrus et al., 2001; Harborth et
al., 2001; Paddison et al., 2002a,b; Sui et al., 2002). These
21- to 23-nucleotide dsRNA molecules induce a down reg-
ulation of transcripts encoded by endogenous genes, or on
transfected plasmids, without inducing global changes in
gene expression often attributed to the expression of longer
dsRNA molecules. A variety of techniques, ranging from
transfection of small dsRNA duplexes (Elbashir et al.,
2001b; Garrus et al., 2001; Harborth et al., 2001) to plas-
mid-based expression of unimolecular, hairpin loop mole-
cules (Abbas-Terki et al., 2002; Barton and Medzhitov,
2002; Brummelkamp et al., 2002a; Carmell et al., 2003;
Kawasaki and Taira, 2003; Paddison et al., 2002b; Sui et al.,
2002; Tiscornia et al., 2003) have been used to introduce
siRNAs into cells, with varying degrees of success.
The ability of siRNAs to down regulate viral gene
expression provides researchers with a powerful tool to
study the replication of viruses encoding proteins from
multiple transcripts, as a complement to the generation of
mutated, recombinant virus and as a genetics technique
for viruses that cannot be manipulated by reverse genet-
ics (Abbas-Terki et al., 2002; Arteaga et al., 2003; Bitko
and Barik, 2001; Coburn and Cullen, 2002; Ge et al.,
2003; Gitlin et al., 2002; Jacque et al., 2002; Kapadia et
al., 2003; Martinez et al., 2002; Qin et al., 2003; Randall
et al., 2003; Seo et al., 2003; Wilson et al., 2003).
However, it is also clear from studies of plant and insect
viruses that endogenous cellular pathways can induce an
RNA interference phenomenon capable of down regulat-
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ing viral gene expression (Baulcombe, 2002; Hutvagner
and Zamore, 2002; Li et al., 2002).
Our studies focused on two viruses that are significant
human and animal pathogens: influenza A virus and West
Nile virus (WNV). Influenza A virus, a member of the
Orthomyxoviridae virus family, is an enveloped, seg-
mented, negative-strand RNA virus that encodes 11 proteins
in the eight RNA segments encompassing its genome (Chen
et al., 2001; Lamb and Krug, 2001). WNV is an enveloped
arbovirus with a single-stranded, 11-kilobase positive-po-
larity RNA genome that belongs to the flavivirus genus of
the Flaviviridae family of viruses. A single open reading
frame is translated from a single genomic promoter located
in the 5 untranslated region (Chambers et al., 1990). While
endemic in parts of Africa, Europe, the Middle East, and
Asia, recent outbreaks in the eastern and midwestern United
States during the past 3 years indicate that it has established
its presence in the Western Hemisphere (Lanciotti et al.,
1999).
In this article, we demonstrate the effectiveness of vec-
tor-based, siRNAs produced under the control of an RNA
polymerase I promoter/terminator cassette at modulating
virus protein expression and infectivity in a sequence-spe-
cific manner. The sensitivity of two mammalian viruses to
siRNAs indicates siRNA technology is a useful, rapid tech-
nique for studying virus replication and holds potential as an
antiviral treatment or diagnostic tool.
Results
RNA interference against influenza A virus
A plasmid-based system for generating unimolecular,
hairpin siRNAs that knockdown expression of the M2 gene
of influenza A virus was established by targeting the 21
contiguous nucleotides present at the M2 mRNA splice
junction. The influenza A virus RNA segment-7 encodes the
M1 protein in a full-length collinear transcript and the M2
protein in a spliced transcript (Figs. 1A and B, and Table 1).
This siRNA (M2-siRNA) should target the M2 mRNA but
not the M1 mRNA, the full-length genomic RNA, or anti-
genomic RNA because the target sequence is not contiguous
in those transcripts. The M2-siRNA was cloned into the
pHH21 plasmid under control of the human RNA polymer-
ase I promoter and murine terminator to produce transcripts
containing precise 5 and 3 ends with no modifications
such as 5 m7G capping or 3 polyadenylate tail sequences
(Fig. 1A).
The effect of M2-siRNA on the expression of M2 and an
M1–GFP fusion protein was determined by flow cytometry.
Transfection of 293T cells with plasmids encoding the
cDNAs for M2 and M1-GFP along with pHH21 resulted in
30% of the cells expressing both M2 and M1-GFP (Fig. 1C,
upper right quadrant) and 13% expressing M1-GFP alone
(Fig. 1C, lower right quadrant). When the pHH21 M2-
siRNA plasmid was included in the transfection, the double-
positive cell population was reduced to 16% with a con-
comitant increase in the M1-GFP single-positive cells to
27% (Fig. 1D), indicating the M2-siRNA reduced the ex-
pression of M2 without altering the expression of M1-GFP
(M1-GFP-positive cells were 43% of the total population for
both Figs. 1C and D). The extent of M2 down regulation
was quantitated by assessing the mean channel fluorescence
(MCF) of the cells in the upper and lower right quadrants of
Figs. 1C and D. The level of M2 expression at the cell
surface was significantly reduced (MCF from 762 to 135),
whereas the M1-GFP levels were virtually unchanged (MCF
from 1944 to 1810). To further define the specificity of
M2-siRNA, 293T cells were transfected with pHH21 M2-
siRNA and pC M2res, an M2 expression plasmid containing
four nucleotide changes within the 21-nucleotide region
recognized by the M2-siRNA. These nucleotide changes
should abolish siRNA recognition of the M2 mRNA but do
not alter the predicted amino acid sequence of M2. The level
of M2 expression from pC M2res was not affected by the
presence of M2-siRNA (Fig. 1E compared to Fig. 1C),
indicating as little as four mismatched nucleotides could
abrogate the siRNA effect. Two additional siRNA vectors
were designed to target M1 (Table 1) and they were able to
knockdown the expression of M1-GFP while not affecting
the level of M2 (Figs. 1G and H compared to 1F). The 5
M1-siRNA (MCF change from 820 to 76) was considerably
more efficient than 3 M1-siRNA (MCF changes from 820
to 204). Thus, unimolecular siRNA expressed from a plas-
mid under control of the RNA polymerase I promoter and
terminator specifically reduce the expression of the target
protein without altering the expression of another protein in
the same cell.
The ability of M2-siRNA to reduce the expression of M2
in influenza A virus infected cells was investigated by
transfecting 293T cells with pHH21 or pHH21 M2-siRNA
followed by infection 24 h later with influenza A virus.
Twelve hours after infection, the cells were harvested and
cell-surface M2 protein was quantitated by flow cytometry.
The cell populations (Figs. 2A and B) were compared using
marker regions that delineate M2 negative-, M2 low-, and
M2 high-expressing cells. M2-siRNA reduced the number of
M2 high-expressing cells (77 to 25%) and increased the M2
low-expressing (11 to 17%) and M2-negative populations
(11.6 to 59%). Thus, the data indicate M2-siRNA are capa-
ble of down regulating expression of virus-encoded M2
protein.
The effect of siRNA-mediated reduction in cell-surface
M2 expression on influenza A virus particle production was
then determined. Transfected 293T cells were infected with
influenza A virus 24 h after transfection. At the indicated
times postinfection, infected cell supernatants were har-
vested and assayed for total particles and infectious particles
(Fig. 2C). At each time point tested, cells that expressed
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M2-siRNA produced fewer total viral particles and infec-
tious virus particles (Fig. 2C) when compared to cells that
were transfected with pHH21. Thus, siRNAs directed
against the M2 transcript not only reduced cell-surface ex-
pression of M2 but also interfered with influenza A virus
particle production.
Fig. 1. Specific down regulation of influenza A virus M2 protein expression by siRNAs. (A) The plasmid pHH21 containing the RNA I polymerase promoter
(P) and terminator (T) was engineered to express a unimolecular RNA transcript containing 21 nucleotides corresponding to nucleotides 18-38 of the M2
cDNA (target sequence), 10 nucleotides constituting a spacer/loop region, 21 nucleotides complementary to the target sequence, and two uridine residues
(M2-siRNA). Transcription yields an RNA transcript predicted to form a hairpin-loop structure. Asterisks indicate the nucleotide positions altered in the M2
expression vector (pC M2res) to make it resistant to M2-siRNA and the arrow indicates the splice junction. (B) Transcription of influenza A virus segment
7 yields a full-length mRNA that encodes the M1 protein. Splicing of a portion of the M1 mRNAs creates the M2 mRNA. The second exon of the M2 mRNA
overlaps but is in a 1 frame with respect to the M1 ORF. A M1-GFP fusion protein was constructed by fusing the carboxyl-terminus of eGFP to the
amino-terminus of M1. 293T cells in 3.5-cm-diameter dishes were transfected (C–H) expression of M2 and M1-GFP) and analyzed by flow cytometry.
Quadrants were set using cells transfected with pCAGGS and pHH21 alone. Cells were transfected as follows: (C) 2.0 g pHH21, 0.5 g pC M2, 0.5 g
pC M1-GFP; (D) 2.0 g pHH21 M2-siRNA, 0.5 g pC M2, 0.5 g pC M1-GFP; (E) 2.0 g pHH21 M2-siRNA, 0.5 g pC M2res, 0.5 g pC M1-GFP; (F)
2.0 g pHH21, 0.5 g pC M2, 0.5 g pC M1-GFP; (G) 2.0 g pHH21 3M1-siRNA, 0.5 g pC M2, 0.5 g pC M1-GFP; or (H) 2.0 g pHH21 5M1-siRNA,
0.5 g pC M2, and 0.5 g pC M1-GFP.
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The amount of M2 protein incorporated into particles was
determined by Western blotting (Fig. 3). Twelve hours
postinfection the infected cell supernatants were collected
and analyzed for total particle production by HA assay. An
equivalent number of particles was analyzed by SDS–
PAGE followed by Western blotting with M2- and NP-
specific monoclonal antibodies. The amount of M2 incor-
porated into virions was increased by only 0.75%, while the
amount of NP protein increased by 39.2% (Fig. 3) when
virus from siRNA expressing cell supernatants was com-
pared to control transfected cells. The data indicate that
particles released from the cell population transfected with
pHH21 M2-siRNA contain wild-type levels of M2, but an
increased amount of NP.
Murine siRNA expression vector
To assess the ability of plasmids expressing siRNAs
under control of the murine RNA polymerase I to down
regulate gene expression in murine or hamster cells (the
murine RNA polymerase I promoter is active in hamster cell
lines), we constructed plasmid derivatives of pRF42 (Flick
and Pettersson, 2001) that express siRNAs to the same
target sequences described in Table 1. The ability of pRF42
M2-siRNA to knockdown the expression of plasmid-ex-
pressed M2 was examined in BHK cells. BHK cells were
transfected with vector or pRF42 M2-siRNA and pC M2 or
pC M2res and analyzed by flow cytometry for M2 surface
expression. Only 6% of cells transfected with pRF42 M2-
siRNA expressed M2 at the cell surface as compared to 56%
in vector control cells (Table 2), while cells transfected with
pC M2res were unaffected by the presence of M2-siRNA.
Consistent with our previous results in 293T cells (Figs. 2A
and B), M2 expression in influenza A virus infected BHK
cells was also reduced in the presence of M2-siRNAs.
Approximately 89% of influenza A virus infected BHK
cells transfected with control vector were positive for M2
expression; this dropped to 38% in cells transfected with
pRF42 M2-siRNA (Table 2). The data indicate that the
pRF42 vector siRNA activity in BHK cells is comparable to
the pHH21 vector in 293T cells.
RNA interference against West Nile virus
The ability of plasmid-expressed siRNAs to down regu-
late gene expression of WNV, a positive-strand RNA virus,
possessing a genome encoding a single open reading frame
(order of encoded proteins: C, M, E, NS1, NS2A, NS2B,
NS3, NS4A, NS4B, and NS5) and lacking subgenomic
promoters, was then investigated. WNV capsid or NS5 ORF
specific siRNAs were constructed in pHH21 (Table 1) and
transfected into 293T cells and the cells subsequently in-
fected with WNV 24 h later. One day after infection, cells
were analyzed by flow cytometry for viral antigen-positive
cells using an antibody against the envelope protein (Table
3). If the WNV-specific siRNAs down regulated all tran-
scripts containing the capsid gene or NS5 sequence, then the
expression of WNV envelope protein should also be re-
duced. Table 3 clearly demonstrates the number of WNV
envelope antigen-positive cells, normalized to vector con-
trol cells, was reduced in cells transfected with a plasmid
encoding either the WNV-CAP-siRNA (30%) or the WNV-
NS5-siRNA (17%) when compared to cells transfected with
pHH21 (100%) or a plasmid encoding M2-siRNA (103%).
The reduction in the percentage of antigen-positive cells
was consistent and reproducible, but little change was ob-
served in the mean channel fluorescence of the remaining
WNV antigen-positive cells (Table 3). The WNV antigen-
positive cells likely represent a population of cells that did
not acquire WNV-siRNA during transfection and thus were
completely permissive for WNV infection.
The specific inhibition of WNV gene expression by
WNV-siRNAs was confirmed after infection with dengue
virus (DV), a related flavivirus. Expression of the M2-
siRNA or the WNV-CAP-siRNA had no significant effect
on the number of DV antigen-positive cells or the mean
channel fluorescence intensity of those cells (Table 3).
However, expression of the WNV-NS5-siRNA consistently
resulted in a slight reduction in the number of DV antigen-
positive cells (Table 3). Sequence alignment indicated that
19 of 21 nucleotides comprising the WNV-NS5 target se-
quence were identical to those present in the corresponding
region of the DV NS5 gene (data not shown). This high
sequence identity most likely causes a partial siRNA-medi-
ated inhibitory effect in DV-infected cells. The effect of
WNV-siRNA on the amount of viral RNA was demon-
strated by performing quantitative, real-time fluorogenic
RT-PCR on RNA from WNV or DV-infected cells that
expressed different siRNAs. Expression of WNV-CAP-
siRNA resulted in a 65% decrease in levels of WNV RNA
(Fig. 4) when compared to cells transfected with pHH21.
M2-siRNA expression had no inhibitory effect on the level
of WNV RNA, and neither M2-siRNA nor WNV-CAP-
siRNA decreased DV RNA levels.
A time-course experiment was performed to determine
Table 1
Sequence of the RNA polymerase I transcribed siRNAs and targets
siRNA Target sequencea Target
M2-siRNA GGTCGAAACGCCTATCAGAAA pC M2/rWSN
— A––G––G––A––––––––––– pC M2res
5 M1-siRNA GGTCGAAACGTATGTTCTCTC pC M1-GFP
3 M1-siRNA AATTTGCAGGCCTATCAGAAA pC M1-GFP
WNV CAP GAACAAACAAACAGCGATGAA WNV
— T––A–––TC––A–––T––T–– DV
WNV NS5 CAGAGCCATTTGGTTCATGTG WNV
— –––––––––A––––A–––––– DV
a The target sequence refers to the sequence recognized by the siRNA, as
well as the vector/virus containing that sequence. In cases where siRNAs
were not designed to a target sequence, a dash (–) appears under the siRNA
column.
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how long the inhibition of viral gene expression would last
after plasmid transfection. At various times after transfec-
tion, 293T cells were infected with WNV and 1 day later the
levels of viral antigen-positive cells and infectious virus
were quantitated (Fig. 5). The expression of WNV-CAP-
siRNA reduced the number of viral antigen-positive cells
(Fig. 5B) as well as the infectious virus titer (Fig. 5C) at all
time points tested through 96 h after transfection, suggest-
ing prolonged expression of inhibitory siRNAs. Moreover,
transfection of WNV-CAP siRNA 1 h after WNV infection
still inhibited gene expression, indicating that the plasmid-
derived siRNAs rapidly accumulated and aborted WNV
infection. The WNV-CAP siRNA did not alter the expres-
sion of DV antigen at any time point tested (Fig. 5A). In
addition, expression of M2-siRNA did not alter the percent-
age of WNV or DV antigen-positive cells or reduce infec-
tious virus titers (Figs. 5B and C). Taken together, these
results indicate plasmid-expressed siRNAs can serve as
rapid, potent, and long-lasting inhibitors of viral gene ex-
pression.
Fig. 2. Down regulation of M2 expression in influenza A virus-infected cells results in decreased virus particle budding. 293T cells in 6-cm-diameter dishes
were transfected with (A) 10.5 g pHH21 and 1.5 g pC, (B) 10.5 g pHH21 M2-siRNA and 1.5 g pC infected with recombinant influenza A virus rWSN
M1 V41A at 24 h posttransfection and analyzed for virus production and cell-surface expression of M2 by flow cytometry at 12 h after infection. (C) At the
indicated times after infection, cell-culture supernatants were harvested and analyzed for hemagglutination titer and infectious virus titer.
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Discussion
In mammalian cells, RNA interference is a sequence-
specific process whereby 21- to 23-nucleotide double-
stranded RNA initiates gene silencing of homologous
mRNA transcripts. In this rapidly evolving field, recent
studies have expressed unimolecular siRNAs under the con-
trol of the RNA polymerase III promoters and used this to
silence reporter gene expression (Paddison et al., 2002a,b;
Sui et al., 2002). Here, we utilize unimolecular siRNAs that
act as antiviral agents using an RNA polymerase I expres-
sion system. Expression of antiviral siRNAs abrogates RNA
replication, antigen expression, and the production of infec-
tious virus in segmented negative-strand RNA (influenza A
virus) and nonsegmented positive-strand (WNV) RNA vi-
rus-infected cells in a sequence-specific manner. Expression
of M2-siRNA inhibits the production of influenza A virus
particles but has no effect on WNV infection. The M2-
siRNA does not alter M1 gene expression because the M1
mRNA contains only 10 or 11 contiguous regions identical
to the M2-siRNA, while the M2 transcript contains all 21
nucleotides in the target sequence. Altering four nucleotides
in the target sequence abolishes the M2-siRNA effect, pro-
viding a means to complement the down regulated form of
the protein with one resistant to RNAi. The natural variation
of two nucleotides in the NS5 gene between WNV and DV
results in siRNAs that completely inhibit WNV but only
partially inhibits DV. Kinetic analyses revealed that expres-
sion of siRNAs induces a durable antiviral state in cells as
only small reductions in inhibitory activity were observed 4
days after transfection. Thus, the engineering and expres-
sion of siRNAs from a plasmid construct enables the induc-
tion of a specific, durable antiviral state against either neg-
ative- or positive-strand viruses.
The human and murine ribosomal RNA polymerase I
promoters (Flick and Pettersson, 2001; Neumann et al.,
1999) were used to generate unimolecular siRNAs hairpin
constructs containing two or three nucleotide 3 overhangs.
The RNA polymerase I cassette system provides an alter-
native to the RNA polymerase III system (Brummelkamp et
al., 2002a), modified RNA polymerase II driven systems
(Xia et al., 2002), or micro-RNAs (Zeng et al., 2002), all of
which can generate functional amounts of interfering
RNAs. The RNA polymerase I promoter/terminator pro-
vides high-level expression of the encoded sequence and
allows for precise delineation of the terminal 3 sequences
due to the nature of the RNA polymerase I terminator and
the cloning strategy employed (Flick et al., 1996; Neumann
et al., 1994; Zobel et al., 1993). Thus, selected siRNAs
sequences can be rapidly inserted into the RNA polymerase
I expression system for assessing the effect of gene silenc-
ing on endogenous or exogenous transcripts.
The use of dsRNA longer than 50 nucleotides in length
in mammalian cells results in a global “antiviral state” due
to the nonspecific degradation of mRNAs and the shutdown
of host cell protein synthesis mediated by activation of
Toll-like receptor 3 or protein kinase R (Alexopoulou et al.,
2001; Samuel, 2001). The expression of unimolecular 21-
nucleotide dsRNA against either influenza or West Nile
viruses mediates an efficient, specific antiviral activity ca-
pable of abrogating viral RNA and protein production with-
out inducing global down regulation of gene expression.
Similar siRNA strategies have been utilized to target viral
and cellular factors that are important in virus replication
with a host of other viruses (Abbas-Terki et al., 2002;
Arteaga et al., 2003; Bitko and Barik, 2001; Coburn and
Cullen, 2002; Ge et al., 2003; Gitlin et al., 2002; Jacque et
al., 2002; Kapadia et al., 2003; Martinez et al., 2002; Qin
et al., 2003; Randall et al., 2003; Seo et al., 2003; Wilson et
al., 2003). The expression of antiviral siRNAs may not
uniformly generate an antiviral state as some animal and
plant RNA viruses (Li et al., 2002) naturally express sup-
pressors of RNA interference. It seems abundantly clear that
most if not all viruses that infect mammalian cells lack such
specific suppressors and thus do not have a “defense”
against siRNA-mediated antiviral activity (Cullen, 2002;
Lindenbach and Rice, 2002; Silva et al., 2002).
Table 2
Down regulation of cDNA expressed M2 and influenza A virus
expressed M2 using siRNAs transcribed from a murine
RNA polymerase I cassette
Expression
vector
Infected siRNA % of Cells
positive for
M2
Mean
channel
fluorescence
pC M2 — Empty Vector 56 592
pC M2 — siRNA 6 59
pC M2res — siRNA 60 701
— rWSN Empty Vector 89 210
— rWSN siRNA 38 298
Fig. 3. M2 siRNA expression does not significantly affect the amount of M2
incorporated into released virions. 293T cells in 3.5-cm-diameter dishes
were transfected with 4 g of either pHH21 or pHH21 M2-siRNA and
infected with rWSN V41A 24 h posttransfection. At 12 h postinfection,
infected-cell supernatants were collected and an equivalent amount of virus
particles (based on HAU) was analyzed by Western blotting using MAbs
specific for the M2 or NP proteins.
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The expression of antiviral siRNAs provides virologists
with a valuable tool for modulating gene expression. For
viruses such as influenza that have segmented genomes with
spliced gene products, siRNAs enable the knockdown and
functional assessment of individual genes without altering
the expression of other virus-encoded genes, providing the
targeted genes do not play a role in viral RNA transcription
or replication (Ge et al., 2003). Utilizing this approach, we
have shown that the M2 protein of influenza A virus plays a
role in the assembly of infectious virus particles. A role for
M2 in virus assembly has been implicated previously using
recombinant viruses that contain mutations in the M2 coding
region (Castrucci and Kawaoka, 1995; Watanabe et al.,
2001) or monoclonal antibodies (14C2) that block M2 func-
tion (Roberts et al., 1998; Zebedee and Lamb, 1988, 1989).
Furthermore, a recombinant influenza A virus with a func-
tional deletion of the M2 protein could be rescued but
replicated poorly in cell culture compared to the wild-type
virus, while a recombinant virus lacking ion channel activ-
ity displayed near wild-type kinetics (Watanabe et al.,
2001). The latter finding differed from the result of Takeda
et al., who found the M2 ion channel activity is required for
efficient viral replication (Takeda et al., 2002). While influ-
enza A virus strains seem to differ with respect to the
absolute requirement for M2 ion channel activity, it seems
clear that the M2 protein performs other functions in the
virus life cycle. Interestingly, our data demonstrate that
M2-siRNAs inhibit virus particle formation to a similar
degree seen with sensitive viral strains grown in the pres-
ence of 14C2 (M. McCown, and A. Pekosz, unpublished
data).
A screen can now be performed to determine whether M2
is a requirement in viral assembly for most, if not all,
influenza A viruses and the development of a trans-comple-
mentation system using siRNA-resistant M2 cDNAs will
allow for a detailed analysis of the domains of M2 that play
a role in assembly. The significance of increased NP incor-
poration into virus particles from cells expressing M2
siRNAs is not clear at this time. Future studies aimed at
quantitating the number of viral genomes packaged into
influenza A virus particles may help explain these results.
The data presented provide evidence that a plasmid-
based vector can generate unimolecular siRNAs that spe-
cifically block expression of viral genes and thus replication
of negative- or positive-strand RNA viruses and extends the
results of others by knocking down the expression of a
single, nonessential gene and showing the importance of
that protein on the life cycle of wild-type virus. These
plasmids and experimental approaches have an immediate
use in cell culture to perturb the expression of individual
viral and host cell genes, providing another tool to further
our understanding of the molecular basis of infection.
Table 3
Effect of siRNA on DV and WNV infection
siRNA Dengue virus West Nile virus
% Positive cells
(normalized)
MFI no. exp. % Positive cells
(normalized)
MFI no. exp.
pHH21 100 73 12 n  8 100 40 9 n  8
M2-siRNA 98  11 69  14 n  8 103  13 42  9 n  8
WNV Cap 87  9 78  9 n  8 30  8** 44  8 n  8
WNV NS5 67  8*** 76  5 n  8 17  6** 40  3 n  3
Note. 293T cells were transfected with vector alone (pHH21) or cDNA encoding siRNA (M2- siRNA, WNV-Cap, or WNV-NS5) and then infected with
DV or WNV. Cells were harvested and processed by flow cytometry. The data are expressed as the percentage of cells expressing either DV or WNV envelope
protein and were normalized to the vector control. The antigen-positive cells are defined as cells possessing greater mean channel fluorescence than
mock-infected cells. DV or WNV expression in pHH21-transfected cells ranged from 30 to 60%. MFI represents the mean linear fluorescence intensity of
the cells expressing viral antigen. The number of experiments for each condition is indicated. Significant differences as determined by a two-tailed paired
t-test are indicated as follows: **P  0.0001, ***P  0.01
Fig. 4. The effect of siRNAs targeting the WNV capsid and NS5 genes on
WNV or DV RNA expression. 293T cells were transfected with pHH21,
pHH21 M2-siRNA, pHH21 WNV-CAP-siRNA, or pHH21 WNV-NS5-
siRNA. One day later, cells were infected with WNV or DV and were
harvested for WNV or DV RNA quantitation by real-time fluorogenic
RT-PCR the following day. Samples were run in triplicate and reflect the
average of three different experiments. The amount of viral RNA is
normalized to cells transfected with the vector control (pHH21) and in-
fected with WNV or DV.
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Materials and methods
Cells and viruses
Human embryonal kidney cells (293T), HeLaT4 cells,
and Madin–Darby canine kidney (MDCK) cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), penicil-
lin, and streptomycin as described previously (Diamond et
al., 2000b; Pekosz and Lamb, 1997). BHK21-15 hamster
kidney cells were maintained in RPMI 1640 supplemented
with 10% FBS, penicillin, and streptomycin. The recombi-
nant influenza A virus strains used were either rWSN V41A
(the A/WSN/33 (rWSN) strain with a nucleotide change in
the M1 ORF changing valine at position 41 to alanine) or
rWSN M2Ud82-93 (possessing the following amino acids
change in the M2 cytoplasmic tail: N82S, V86A, G89S, and
N93S). Both strains were generated wholly from plasmid
(Neumann et al., 1999; Takeda et al., 2002). The DV strain
used was a prototype DHF type-2 strain (16681) from Thai-
land (Russell and Nisalak, 1967). The WNV strain
(3000.0259, passage 1) was isolated from a mosquito in
New York in 2000 (Ebel et al., 2001).
Antibodies
The 14C2 monoclonal antibody recognizes an epitope in
the extracellular domain of the influenza A virus M2 protein
(Zebedee and Lamb, 1988), while the HB-64 monoclonal
antibody recognizes the NP protein (Yewdell et al., 1981).
The monoclonal antibody 4G2 (American Type Culture
Collection, Manassas, VA) recognizes a conserved epitope
in the envelope protein of DV or WNV (Brandt et al., 1982).
Plasmids and transfections
The plasmid pHH21 (Neumann et al., 1999), containing
the human RNA polymerase I promoter and the murine
RNA polymerase I terminator (which is functional in human
cells), and pRF42 (Flick and Pettersson, 2001), containing
the murine RNA polymerase I promoter and terminator,
were used to generate short, unimolecular RNA transcripts
which serve as siRNAs. Oligonucleotide pairs which, after
annealing, generate double-stranded DNA fragments that
contain a 5 overhang, 21-nucleotides identical to the tar-
geted transcript, a 10-nucleotide hairpin loop, 21-nucleo-
tides complementary to the target transcript sequence, two
or three thymidine residues, and a 3 overhang (oligonucle-
otide sequences available upon request) were cloned into
BsmBI-digested pHH21 or BbsI-digested pRF42. The target
sequences chosen were as follows: influenza A virus M2
cDNA nucleotides 18-38 (which span the splice junction),
influenza A virus M1 cDNA nucleotides 18-38 (5M1-
siRNA), and 706-726 (3M1-siRNA), the WNV capsid gene
nucleotides 312-332, and the WNV NS5 gene nucleotides
9099-9119 (Table 1).
A cDNA encoding the M2 protein from A/Udorn/72 (pC
M2) was constructed by polymerase chain reaction (PCR)
using oligonucleotide primers (primer sequence available
upon request) followed by cloning into the eukaryotic ex-
pression vector pCAGGS (Niwa et al., 1991). The plasmid
pC M2res was created by introducing four translationally
silent nucleotide changes at the following locations of the
M2 cDNA: G18A, C21G, A24G, and G27A. An M1–GFP
fusion protein (M1 from influenza A/Udorn/72, GFP from
peGFP, Clontech, Palo Alto, CA) was constructed by elim-
inating the stop codons from the eGFP cDNA and fusing the
3 end of the eGFP coding region to the 5 end of the M1
coding region using four primer PCR (primer sequences
available upon request), followed by cloning into pCAGGS
(pC M1-GFP). The M1-GFP protein is identical to the M1
protein with respect to intracellular targeting and turnover
rate (J.K. Ly and A. Pekosz, unpublished results). All plas-
Fig. 5. Time course of siRNA-mediated inhibition. 293T cells were in-
fected with (A) DV or (B) WNV either before (1 h) or after (24, 48,
72, 96 h) transfection with pHH21, pHH21 M2-siRNA, or pHH21
WNV-CAP-siRNA. One day after infection, cells were harvested and
processed for flow cytometry. The data are the average of three or eight
experiments per time point and are expressed as the percentage of DV or
WNV antigen-positive cells, normalized to the vector control. (C) 293T
cells were transfected with siRNA and infected with WNV as described in
(A). One day after infection, supernatants were harvested and titered for
infectious virus by plaque assay with BHK21 cells. The data are the
average of three experiments per time point, expressed as the number of
plaque forming units (PFU) per milliliter normalized to the vector control.
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mids were sequenced to ensure the fidelity of the encoded
transcripts.
293T or BHK cells were transfected with the indicated
amounts of plasmid DNA and Trans IT LT-1 (Mirus Corp.,
Madison, WI) according to the manufacturer’s instructions.
Briefly, cells were incubated in OptiMEM (Invitrogen,
Carlsbad, CA) and preformed plasmid DNA-LT-1 com-
plexes (1-2 l LT-1 per 1 g of total plasmid DNA) were
added for 6 h at 37°C followed by the addition of an equal
volume of complete DMEM.
Infection and plaque assays
At indicated times posttransfection, cells were infected
with influenza A virus, DV, or WNV at a multiplicity of
infection (m.o.i.) of 1-3 (Diamond et al., 2000a; Zhang et
al., 2000). In one series of experiments, cells were infected
1 h prior to transfection (1 h). Influenza A virus particles
were quantitated by hemagglutination of 0.5% chicken red
blood cell suspension and by plaque assay on MDCK cells
(Paterson and Lamb, 1993). West Nile virus was quantitated
by plaque assay on BHK21-15 cells (Diamond et al., 2000a;
Yamshchikov et al., 2001).
Flow cytometry and Western blotting
Viral antigen expression was quantitated by flow cytom-
etry (FACSCalibur dual laser flow cytometer, Becton–Dick-
inson) as previously described (Diamond et al., 2000a; Pe-
kosz and Lamb, 1999), using the 14C2 monoclonal antibody
(influenza A virus M2 ectodomain) or the 4G2 monoclonal
antibody (flavivirus envelope protein) and murine IgG-spe-
cific secondary antibodies conjugated to fluorescein isothio-
cyanate (FITC, Jackson Laboratories) or AlexaFluor 647
(Molecular Probes). M1-GFP fluorescence was measured
directly.
For Western blotting, infected cell supernatants (1:1 vol-
ume ratio) were mixed with 2 SDS–PAGE sample buffer.
Equivalent particles, based on HA titer, were then loaded
onto a 15% polyacrylamide gel. The polypeptides were
separated by SDS–PAGE and transferred to PVDF mem-
branes using a tank transfer apparatus (Mini Trans-Blot,
Bio-Rad) at 100 V for 1 h. The blot was incubated with
14C2 (1:1000 dilution) and HB-64 (1:1600 dilution) mono-
clonal antibodies followed by a murine IgG-specific sec-
ondary antibody conjugated to horseradish peroxidase
(Jackson Laboratories). The blot was imaged using chemi-
fluorescence (Amersham Biosciences ECLplus) and band
intensities were determined by phosphoimaging (FujiFilm
FLA-5000).
Real-time RT-PCR
Viral RNA was measured by real-time PCR using the
One-Step Taq-Man RT-PCR buffer system and an ABI
7000 Sequence Detection System (Applied Biosystems,
Foster City, CA). To quantitate DV RNA, two primers and
a probe were used corresponding to a sequence in the DV2
3 noncoding region (Houng et al., 2001). To quantitate
WNV RNA, two primers and a probe were used correspond-
ing to a sequence in the envelope protein of WNV (Lanciotti
et al., 2000). The primer probes contained a 5 reporter,
6-carboxyfluorescein (FAM), and a 3 quencher, 6-carboxy-
N,N,N,N-tetramethylrhodamine (TAMRA). The reverse
transcription (RT) step was performed for 30 min at 48°C.
After a 10-min incubation at 95°C, the amplification was
performed, consisting of 40 cycles of 95°C for 15 s and
60°C for 1 min. In parallel, ribosomal RNA (rRNA) was
quantitated from samples for normalization of the number
of cells (Ribosomal RNA Kit, Applied Biosystems). The
absolute levels of viral and ribosomal RNA were deter-
mined according to standard curves with known quantities
of RNA. Data were determined as the number of viral
genomic equivalents per rRNA and then normalized to the
vector (pHH21) control.
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